Urinary N-acetyl-β-D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation

Archives of Disease in Childhood

Volumn 78, Issue 6, 1998, Pages 540-543

  Ring, E ^a,b   Eber, E ^a   Erwa, W ^a   Zach, M S ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

Cystic fibrosis; Gentamicin; Kidney function; N acetyl D glucosaminidase

Indexed keywords

GENTAMICIN; N ACETYL BETA GLUCOSAMINIDASE;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NEBULIZER; NEPHROTOXICITY; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0031748228     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.78.6.540     Document Type: Article

References (27)

1. Zach MS. Lung disease in cystic fibrosis - an updated concept. Pediatr Pulmonol 1990;8:188-202.
2. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594-04.
3. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981;ii: 1137-9.
4. Wall MA, Terry AB, Eisenberg J, McNamara M, Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet 1983;i:1325.
5. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonization in cystic fibrosis. Lancet 1985;i:865.
6. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with pseudomonas aeruginosa. Br J Dis Chest 1987;81:272-9.
7. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8.
8. Steinkamp G, Tümmler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-8.
9. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-8.
10. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7:265-71.
11. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood JR, Kravitz RM. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328: 1740-6.
12. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364-8.
13. Kunin CM, Chesney RW, Craig WA, England AC, DeAngelis C. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-β-glucosaminidase in the general population and in patients with renal disease. Pediatrics 1978;62: 751-60.
14. Price RG. Urinary enzymes, nephrotoxicity and renal disease. Toxicology 1982;23:99-134.
15. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilising pilocarpin by iontophoresis. Pediatrics 1959;23:545-9.
16. Gibb DM, Tomlinson PA, Dalton NR, Turner C, Shah V. Renal tubular proteinuria and microalbuminuria in diabetic patients. Arch Dis Child 1989;64:129-34.
17. Linné T, Fituri O, Escobar-Billing R, et al. Functional parameters and 99m-technetium-dimercaptosuccinic acid scan in acute pyelonephritis. Pediatr Nephrol 1994;8:694-9.
18. Ring E, Erwa W, Zobel G. N-acetyl-β-D-glucosaminidase (NAG) im Urin. Ein zusätzlicher Parameter zur Lokalisationsdiagnostik eines Harnwegsinfekts. Monatsschr Kinderheilkd 1989;137:280-3.
19. Houser MT. The effects of age and urine concentration on lysosome and N-acetyl-β-D-glucosaminidase (NAG) content in urine. Ann Clin Biochem 1986;23:297-302.
20. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136:1445-9.
21. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Davies ER, Carswell F. The quantitative distribution of nebulised antibiotic in the lung in cystic fibrosis. Respir Med 1994;88:203-11.
22. Zach MS. Discussion. Chest 1988;94:S160-1.
23. Mukhopadhyay S, Baer S, Blanshard I, Coleman M, Carswell F. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis. J Antimicrob Chemother 1993;31:429-36.
24. Bentur Y, Hummel D, Roifman CM, Giesbrecht E, Koren G. Interpretation of excessive levels of inhaled tobramycin. Ther Drug Monit 1989;11:109-10.
25. Steinkamp G, Lütge M, Wurster U, Schulz-Baldes JG, Gröne HJ, Ehrich JHH. Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr 1986;145:526-31.
26. Tune BM, Reznik VM, Mendoza SA. Renal complications of drug therapy. In: Holliday MA, Barratt TM, Avner ED, eds. Pediatric nephrology. Baltimore: Williams & Wilkins, 1994:1212-26.
27. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302: 1106-9.